Drug intelligence / Profile preview

TMI-358

Development stage: Discontinued
Lead developer: Talima Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

TMI-358 is a small molecule drug developed by Talima Therapeutics for the topical treatment of onychomycosis, specifically distal subungual onychomycosis (toenail fungus). It was evaluated in clinical trials as a topical therapy to determine its efficacy, safety, and tolerability in treating fungal infections of the toenails. The development reached Phase 2 clinical trials but was ultimately discontinued. The precise mechanism of action and molecular target have not been publicly disclosed.

Beyond the preview

Go deeper on TMI-358.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMI-358.

Explore the full profile